September 19th, 2024 – INCATE, the INCubator for Antibacterial Therapies in Europe, is glad to announce that MSD (known as Merck & Co., Inc., Rahway, NJ in the United States and Canada), a global leader in the development of innovative medicines and vaccines, has extended its partnership which started in 2021 until 2026.

“This is fantastic news for INCATE,” said Timo Jaeger, Managing Director of the German Center for Infection Research (DZIF) and INCATE Board Member. “With this renewed partnership, MSD and INCATE will keep collaborating to select and support groundbreaking early-stage initiatives aimed at combating drug-resistant bacterial infections.”

“At MSD, we are deeply committed to addressing this urgent public health challenge of antimicrobial resistance,” said Dr. med Ahmed Khalifa, Medical Director at MSD in Germany. “By extending our partnership with INCATE, we reaffirm our dedication to fostering innovation and supporting the development of new therapies that can protect and save lives.”

Antimicrobial resistance is a serious global health threat, which puts in danger millions of lives as existing antibiotics become less effective. The extended partnership between MSD Germany and INCATE builds on the successes of their collaboration, which began in 2021, and has been of great importance in selecting the most promising early-stage initiatives in antimicrobial resistance (AMR).

The INCATE support model has proven value for early stage ventures and will continue to develop and strengthen with existing and new partners.

About MSD

At MSD, known as Merck & Co., Inc., Rahway, NJ, in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

For further information visit MSD Deutschland website and follow us on LinkedIn, Instagram and YouTube.     

About INCATE 

INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel are the academic founding members of INCATE with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, MSD, Roche and Shionogi as well as other organizations, funders and investors, INCATE want to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.

For more information please contact:

helena.costa.pereira@incate.net  or +49 176 46172549
www.incate.net
X: @INCATEurope
Linkedin: @INCATE
YouTube: @INCATEurope